Streetbeat News

Price Targets

PEPG

Wedbush analyst Laura Chico has reiterated an Outperform rating on PepGen (NASDAQ:PEPG) and maintained a price target of $21. This reaffirmation of the stock's potential could influence investor sentiment and the stock's short-term performance.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 4:00 pm

SRPT

Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a price target of $224.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 3:55 pm

INZY

Wedbush analyst David Nierengarten has reiterated an Outperform rating on Inozyme Pharma (NASDAQ:INZY) and maintained a $15 price target on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 3:52 pm

RCUS

Wedbush analyst Robert Driscoll has maintained an Outperform rating on Arcus Biosciences (NYSE:RCUS) but reduced the price target from $36 to $30.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 3:46 pm

PPBI

Wedbush analyst David Chiaverini has maintained a Neutral rating on Pacific Premier Bancorp (NASDAQ:PPBI) but has lowered the price target from $31 to $30.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 3:38 pm

HMST

Wedbush analyst David Chiaverini has maintained a Neutral rating on HomeStreet (NASDAQ:HMST) and increased the price target from $15 to $16.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 3:35 pm

BEN

BMO Capital analyst Etienne Ricard has maintained a Market Perform rating on Franklin Resources (NYSE:BEN) and increased the price target from $27 to $30.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 3:28 pm

VZ

Citigroup analyst Michael Rollins has reaffirmed a Buy rating on Verizon Communications (NYSE:VZ) and increased the price target from $45 to $47.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 3:21 pm

FFIV

RBC Capital analyst Matthew Hedberg has maintained a 'Sector Perform' rating on F5 Networks, Inc. (NASDAQ: FFIV) and increased the price target from $185 to $204.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 3:21 pm

HOOK

RBC Capital analyst Brian Abrahams has maintained an Outperform rating on HOOKIPA Pharma (NASDAQ:HOOK) but has reduced the price target from $6 to $5.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 3:15 pm